Welcome to our dedicated page for VIVO news (Ticker: VIVO), a resource for investors and traders seeking the latest updates and insights on VIVO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VIVO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VIVO's position in the market.
Meridian Bioscience, a leader in diagnostic testing, has launched two new master mixes: Lyo-Ready™ Direct DNA qPCR Saliva Mix and Lyo-Ready™ Direct RNA/DNA qPCR Saliva Mix. These mixes enhance the detection of DNA and RNA in crude saliva samples, improving assay sensitivity and simplifying protocols. Designed for use in both liquid and lyophilized formats, they address challenges posed by PCR inhibitors in saliva. This launch comes at a critical time with rising respiratory infections, making saliva testing more urgent. Meridian aims to lead in innovative diagnostic solutions.
Meridian Bioscience (NASDAQ: VIVO) has announced the election of John C. McIlwraith as Chairman of the Board, effective January 26, 2022, succeeding David C. Phillips who retired after over 21 years of service. McIlwraith is a Managing Director at Allos Ventures and has extensive experience in healthcare and technology sectors. His leadership is expected to enhance Meridian's innovation in diagnostics. Meridian is dedicated to developing diagnostic solutions and life science raw materials globally, serving various healthcare sectors.
Meridian Bioscience, Inc. (NASDAQ: VIVO) will report its first quarter 2022 financial results on February 4, 2022. CEO Jack Kenny will host a conference call at 10:00 a.m. Eastern Time to discuss the results. Investors can join the live call via webcast or by telephone. A replay will be available after the call. Meridian offers a range of diagnostic testing solutions and life science raw materials globally, serving various sectors including healthcare and environmental applications.
Meridian Bioscience, a leader in diagnostic testing, announced FDA clearance for its Curian® Campy assay on Jan. 5, 2022. This rapid test detects Campylobacter-specific antigens in fecal specimens, providing results in approximately 20 minutes. The assay enhances patient care by delivering accurate and timely results for campylobacteriosis, a common gastrointestinal infection. The Curian testing platform, which includes the newly cleared assay, aims to streamline testing in laboratories, following the prior clearance of the Curian HpSA® assay in March 2020.
Meridian Bioscience, a provider of diagnostic testing solutions, will participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference. CEO Jack Kenny is set to pre-record a presentation available on January 10, 2022. The webcast can be accessed via Meridian's Investor Relations website, where it will remain available for 90 days. Meridian focuses on innovative diagnostics for various applications and serves clients in over 70 countries. The company's shares trade on NASDAQ under the symbol VIVO.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced the retirement of CFO Bryan Baldasare effective December 31, 2021. Baldasare, who joined the company in 2000 and became CFO in 2019, oversaw significant revenue growth exceeding 500% and global expansion during his tenure. Julie Smith has been appointed as Senior VP and principal accounting officer. The company is engaging an executive search firm for a new CFO. CEO Jack Kenny acknowledged Baldasare's substantial contributions and cited the strong finance organization left behind as a key asset for future continuity.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced the retirement of David Phillips as Chairman of the Board, effective January 2022. Phillips, who joined the board in 2000 and became chairman in 2018, is credited with steering the company through major developments, including Sarbanes-Oxley implementation and numerous acquisitions. Under his leadership, Meridian's employee base and financial performance significantly improved, with fiscal 2021 revenues and earnings per share over five times those of 2000. The board will elect a new chair post-retirement, reducing the board size to eight.
On November 17, 2021, Meridian Bioscience (NASDAQ: VIVO) announced the launch of its innovative Air-Dryable™ LAMP Mix and Air-Dryable™ RT-LAMP 1-Step Mix. These molecular master mixes enable rapid isothermal amplification of nucleic acid sequences, slashing the typical 45-minute result time in half. Designed to facilitate point-of-care testing, the mixes support increased sample sizes and include a pre-optimized buffer system for improved sensitivity and specificity. The developments aim to expedite assay optimization and reduce manufacturing costs, enhancing the overall diagnostic capabilities for test manufacturers.
Meridian Bioscience (NASDAQ: VIVO) reported Q4 and FY2021 financial results with consolidated net revenues of $76.2 million, up 19% year-over-year. For FY2021, revenues rose 25% to $317.9 million, driven by a 43% increase in the Life Science segment and $111.9 million from COVID-19 products. Operating income for Q4 was $8.5 million (11% margin), and FY2021 was $93 million (29% margin). The company faces challenges from product recalls and upcoming FDA approvals. Guidance for FY2022 estimates revenues between $285-$300 million with an adjusted operating margin of 21%-22%.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that the Revogene® SARS-CoV-2 assay has received Emergency Use Authorization (EUA) from the FDA. Shipments are expected to begin before December 31, 2021. This molecular diagnostic test provides results in as little as 47 minutes, boasting a positive predictive agreement (PPA) and negative predictive agreement (NPA) of 97.7%. The assay aims to enhance COVID-19 testing capacity for healthcare systems, addressing the ongoing demand for accurate detection amid emerging variants.
FAQ
What is the market cap of VIVO (VIVO)?
